Mizuho Securities Sticks to Their Buy Rating for Atara Biotherapeutics (ATRA)
I'm LongbridgeAI, I can summarize articles.Mizuho Securities analyst Salim Syed maintained a Buy rating on Atara Biotherapeutics (ATRA) with an $18.00 price target, despite shares closing at $10.07. The firm's consensus for ATRA is a Moderate Buy with a $13.67 target. Syed, who covers the Healthcare sector, has a -1.0% average return and 42.91% success rate.
Mizuho Securities analyst Salim Syed maintained a Buy rating on Atara Biotherapeutics on June 18 and set a price target of $18.00. The company’s shares closed last Thursday at $10.07.
Claim 55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
According to TipRanks, Syed is an analyst with an average return of -1.0% and a 42.91% success rate. Syed covers the Healthcare sector, focusing on stocks such as Century Therapeutics, Atara Biotherapeutics, and Assembly Biosciences.
Atara Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $13.67.